User login
Key clinical point: Hydroxychloroquine treatment conferred survival benefits in a dose-dependent manner in patients with elderly-onset rheumatoid arthritis (RA), with patients receiving a monthly cumulative dose of 1374.5-5778.5 mg or more showing better survival than those receiving <1374.5 mg.
Major finding: Hydroxychloroquine treatment was a protective factor against mortality in patients with elderly-onset RA (hazard ratio 0.30; P = .002), with a cumulative dose of <1374.5 mg vs 1374.5-5,778.5 mg or more leading to the lowest survival rate (P < .001).
Study details: Findings are from a retrospective observational study including 980 patients with elderly-onset RA (disease onset after 60 years of age) who had received conventional synthetic, biologic, or targeted synthetic disease-modifying antirheumatic drugs.
Disclosures: This study was supported by the National Science and Technology Council, Taiwan, and other sources. The authors declared no conflicts of interest.
Source: Lin CT et al. Association of hydroxychloroquine use with a dose-dependent decrease in mortality risk in patients with elderly-onset rheumatoid arthritis. Rheumatol Ther. 2023 (May 12). Doi: 10.1007/s40744-023-00561-1
Key clinical point: Hydroxychloroquine treatment conferred survival benefits in a dose-dependent manner in patients with elderly-onset rheumatoid arthritis (RA), with patients receiving a monthly cumulative dose of 1374.5-5778.5 mg or more showing better survival than those receiving <1374.5 mg.
Major finding: Hydroxychloroquine treatment was a protective factor against mortality in patients with elderly-onset RA (hazard ratio 0.30; P = .002), with a cumulative dose of <1374.5 mg vs 1374.5-5,778.5 mg or more leading to the lowest survival rate (P < .001).
Study details: Findings are from a retrospective observational study including 980 patients with elderly-onset RA (disease onset after 60 years of age) who had received conventional synthetic, biologic, or targeted synthetic disease-modifying antirheumatic drugs.
Disclosures: This study was supported by the National Science and Technology Council, Taiwan, and other sources. The authors declared no conflicts of interest.
Source: Lin CT et al. Association of hydroxychloroquine use with a dose-dependent decrease in mortality risk in patients with elderly-onset rheumatoid arthritis. Rheumatol Ther. 2023 (May 12). Doi: 10.1007/s40744-023-00561-1
Key clinical point: Hydroxychloroquine treatment conferred survival benefits in a dose-dependent manner in patients with elderly-onset rheumatoid arthritis (RA), with patients receiving a monthly cumulative dose of 1374.5-5778.5 mg or more showing better survival than those receiving <1374.5 mg.
Major finding: Hydroxychloroquine treatment was a protective factor against mortality in patients with elderly-onset RA (hazard ratio 0.30; P = .002), with a cumulative dose of <1374.5 mg vs 1374.5-5,778.5 mg or more leading to the lowest survival rate (P < .001).
Study details: Findings are from a retrospective observational study including 980 patients with elderly-onset RA (disease onset after 60 years of age) who had received conventional synthetic, biologic, or targeted synthetic disease-modifying antirheumatic drugs.
Disclosures: This study was supported by the National Science and Technology Council, Taiwan, and other sources. The authors declared no conflicts of interest.
Source: Lin CT et al. Association of hydroxychloroquine use with a dose-dependent decrease in mortality risk in patients with elderly-onset rheumatoid arthritis. Rheumatol Ther. 2023 (May 12). Doi: 10.1007/s40744-023-00561-1